Seminars in Pediatric Surgery
Volume 15, Issue 3 , Pages 179-187 , August 2006

Malignancy in pediatric transplant recipients

  • Joseph F. Buell, MD

      Affiliations

    • The Israel Penn International Transplant Tumor Registry, Division of Transplantation, University of Cincinnati, Cincinnati, Ohio
    • Corresponding Author InformationAddress reprint requests and correspondence: Joseph F. Buell, MD, University of Cincinnati, The Israel Penn International Tranpslant Tumor Registry, Division of Transplantation, 231 Albert Sabin Way, Cincinnati, OH 45267.
    • ,
  • Thomas G. Gross, MD, PhD

      Affiliations

    • Division of Pediatric Hematology Oncology, Columbus Children’s Hospital, Columbus, Ohio
    • ,
  • Mark J. Thomas, MD

      Affiliations

    • The Israel Penn International Transplant Tumor Registry, Division of Transplantation, University of Cincinnati, Cincinnati, Ohio
    • ,
  • Guy Neff, MD

      Affiliations

    • The Israel Penn International Transplant Tumor Registry, Division of Transplantation, University of Cincinnati, Cincinnati, Ohio
    • ,
  • Chandar Muthiah

      Affiliations

    • The Israel Penn International Transplant Tumor Registry, Division of Transplantation, University of Cincinnati, Cincinnati, Ohio
    • ,
  • Rita Alloway, PharmD

      Affiliations

    • The Israel Penn International Transplant Tumor Registry, Division of Transplantation, University of Cincinnati, Cincinnati, Ohio
    • ,
  • Frederick C. Ryckman, MD

      Affiliations

    • Division of Pediatric Surgery, Cincinnati’s Children’s Hospital, Cincinnati, Ohio.
    • ,
  • Gregory M. Tiao, MD

      Affiliations

    • The Israel Penn International Transplant Tumor Registry, Division of Transplantation, University of Cincinnati, Cincinnati, Ohio
    • ,
  • E. Steve Woodle, MD

      Affiliations

    • The Israel Penn International Transplant Tumor Registry, Division of Transplantation, University of Cincinnati, Cincinnati, Ohio

References 

  1. Buell JF , Gross TG , Woodle ES . Malignancy and Transplantation . Transplantation . 2005;80(2):S254–S264
  2. Penn I . Cancers in renal transplant recipients . Adv Ren Replace Ther . 2000;7:147–156
  3. Penn I . Post-transplant malignancy (the role of immunosuppression) . Drug Saf . 2000;23:101–113
  4. Penn I . Occurrence of cancers in immunosuppressed organ transplant recipients . In:  Cecka JM ,  Terasaki PI editor. Clin Transpl . Los Angeles, CA: UCLA Tissue Typing Laboratory; 1998;p. 147–152
  5. Engels EA , Goedert JJ . Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer (past, present, and future) . J Natl Cancer Inst . 2005;97:407–409
  6. Muller AM , Ihorst G , Mertelsmann R , Engelhardt M . Epidemiology of non-Hodgkin’s lymphoma (NHL) (trends, geographic distribution, and etiology) . Ann Hematol . 2005;84:1–12
  7. Moore PS , Gao SJ , Dominguez G , et al.   Primary characterization of a herpesvirus agent associated with Kaposi’s sarcomae . J Virol . 1996;70:549–558
  8. Penn I . Kaposi’s sarcoma in transplant recipients . Transplantation . 1997;64(-73):669
  9. Woodle ES , Hanaway M , Buell J , et al.   Kaposi sarcoma (an analysis of the US and international experiences from the Israel Penn International Transplant Tumor Registry) . Transplant Proc . 2001;33:3660–3661
  10. Meyer T , Arndt R , Nindl I , Ulrich C , Christophers E , Stockfleth E . Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients . Transpl Int . 2003;16:146–153
  11. Euvrard S , Chardonnet Y , Pouteil-Noble C , et al.   Association of skin malignancies with various and multiple carcinogenic and noncarcinogenic human papillomaviruses in renal transplant recipients . Cancer . 1993;72:2198–2206
  12. Diehl V , Hauch P , Harris N . Hodgkin’s disease . In:  DeVita VT ,  Hellman S ,  Rosenberg S editor. Cancer Principles and Practice of Oncology . Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 2339–2343
  13. Yarchoan R , Little RF . Immunosuppression-related malignancies . In:  DeVita VT ,  Hellman S ,  Rosenberg SA editor. Cancer (Principles and Practice of Oncology) . Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 2575–2581
  14. Ebb DH , Green DM , Schanberger RC , Tarbell NJ . Solid tumors of childhood . In:  DeVita VT ,  Hellman S ,  Rosenberg SA editor. Cancer (Principles and Practice of Oncology) . Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 2169–2172
  15. Gurney JG , Bondy ML . Epidemiology of childhood cancer . In:  Pizzo PA ,  Poplack DG editor. Principles and Practice of Pediatric Oncology . ed 5. Philadelphia, PA: Lippincott, Williams and Wilkins; 2005;p. 1–13
  16. Guba M , Graeb C , Jauch KW , Geissler EK . Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation . Transplantation . 2004;77:1777–1782
  17. Taylor L , Hughes RA , McPherson K . The risk of cancer from azathioprine as a treatment for multiple sclerosis . Eur J Neurol . 2004;11:141–147
  18. Beauparlant P , Papp K , Haraoui B . The incidence of cancer associated with the treatment of rheumatoid arthritis . Semin Arthritis Rheu . 1999;29:148–158
  19. Fung JJ , Jain A , Kwak EJ , Kusne S , Dvorchik I , Eghtesad B . De novo malignancies after liver transplantation (a major cause of late death) . Liver Transpl . 2001;7:S109–S118
  20. Swinnen LJ , Fisher RI . OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10 (a possible cause of lymphoproliferative disorders associated with transplantation) . Curr Opin Nephrol Hypertens . 1993;2:670–678
  21. Lenner R , Padilla ML , Teirstein AS , Gass A , Schilero GJ . Pulmonary complications in cardiac transplant recipients . Chest . 2001;120:508–513
  22. Cherikh WS , Kauffman HM , McBride MA , Maghirang J , Swinnen LJ , Hanto DW . Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation . Transplantation . 2003;76:1289–1293
  23. Dharnidharka VR , Sullivan EK , Stablein DM , Tejani AH , Harmon WE . Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation (a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)) . Transplantation . 2001;71:1065
  24. Buell J , Hanaway M , Thomas M , Rudich S , Woodle E . Malignancies associated with liver transplantation . In:  Busuttil RW ,  Klintmalm GB editor. Transplantation of the Liver . Philadelphia, PA: W.B. Saunders; 2004;
  25. Ruiz P , Soares MF , Garcia M , et al.   Lymphoplasmacytic hyperplasia (possibly pre-PTLD) has varied expression and appearance in intestinal transplant recipients receiving Campath immunosuppression . Transplant Proc . 2004;36:386–387
  26. Herman M , Weinstein T , Korzets A , et al.   Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients . J Lab Clin Med . 2001;137:14–20
  27. Guba M , Graeb C , Jauch KW , Geissler EK . Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation . Transplantation . 2004;77:1777–1782
  28. Hojo M , Morimoto T , Maluccio M , et al.   Cyclosporine induces cancer progression by a cell-autonomous mechanism . Nature . 1999;397:530–535
  29. Shihab FS , Bennett WM , Isaac J , Yi H , Andoh TF . Nitric oxide modulates vascular endothelial growth factor and receptors in chronic cyclosporine nephrotoxicity . Kidney Int . 2003;63:522–533
  30. Reichenspurner H . Overview of tacrolimus-based immunosuppression after heart or lung transplantation . J Heart Lung Transplant . 2005;24:119–124
  31. Mistrikova J , Mrmusova M , Durmanova V , Rajcani J . Increased neoplasm development due to immunosuppressive treatment with FK-506 in BALB/C mice persistently infected with the mouse herpesvirus (MHV-72) . Viral Immunol . 1999;12:237–247
  32. Sakai M , Miyake H , Tashiro S , Okumura Y , Kido H . Inhibitory effect of FK506 and cyclosporine A on the growth and invasion of human liver cancer cells . J Med Invest . 2004;51:63–68
  33. Jain A , Nalesnik M , Reyes J , et al.   Posttransplant lymphoproliferative disorders in live transplantation (A 20-year experience) . Ann Surg . 2002;236(4):429–437
  34. Taylor L , Hughes RA , McPherson K . The risk of cancer from azathioprine as a treatment for multiple sclerosis . Eur J Neurol . 2004;11:141–147
  35. Beauparlant P , Papp K , Haraoui B . The incidence of cancer associated with the treatment of rheumatoid arthritis . Semin Arthritis Rheum . 1999;29:148–158
  36. Tressler RJ , Garvin LJ , Slate DL . Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo . Int J Cancer . 1994;57:568–573
  37. Weber G , Hager JC , Lui MS , et al.   Biochemical programs of slowly and rapidly growing human colon carcinoma xenografts . Cancer Res . 1981;41:854–859
  38. Natsumeda Y , Prajda N , Donohue JP , Glover JL , Weber G . Enzymic capacities of purine de Novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues . Cancer Res . 1984;44:2475–2480
  39. Nagai M , Natsumeda Y , Konno Y , Hoffman R , Irino S , Weber G . Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias . Cancer Res . 1991;51:3886–3890
  40. Jackson RC , Weber G , Morris HP . IMP dehydrogenase, an enzyme linked with proliferation and malignancy . Nature . 1975;256:331–336
  41. Yu J , Lemas V , Page T , Connor JD , Yu AL . Induction of erythroid differentiation in K562 cells by inhibitors of inosine monophosphate dehydrogenase . Cancer Res . 1989;49:5555–5560
  42. Ohsugi Y , Suzuki S , Takagaki Y . Antitumor and immunosuppressive effects of mycophenolic acid derivatives . Cancer Res . 1976;36:2923–2927
  43. Carter SB , Franklin TJ , Jones DF , et al.   Mycophenolic acid (an anti-cancer compound with unusual properties) . Nature . 1969;223:848–852
  44. Buell J , Hanaway M , Thomas M , Rudich S , Woodle E . Malignancies associated with liver transplantation . In:  Busuttil RW ,  Klintmalm GB editor. Transplantation of the Liver . Philadelphia, PA: W.B. Saunders; 2004;
  45. Buell J , Gross T , Beebe T , et al.   Cancer after renal transplantation . In:  Cohen EP editors. Cancer and the Kidney . New York, NY: Oxford University Press; 2004;
  46. Trofe J , Beebe TM , Buell JF , et al.   Posttransplant malignancy . Prog Transplant . 2004;14:193–204
  47. Yakupoglu Y , Knight R , Katz S . Low incidence of malignancy among sirolimus-cyclosporine treated transplant recipients . Am J Transplant . 2004;3(suppl 5):187
  48. Trotter JF . Sirolimus in liver transplantation . Transplant Proc . 2003;35:193S–200S
  49. Luan FL , Ding R , Sharma VK , Chon WJ , Lagman M , Suthanthiran M . Rapamycin is an effective inhibitor of human renal cancer metastasis . Kidney Int . 2003;63:917–926
  50. Nepomuceno RR , Balatoni CE , Natkunam Y , Snow AL , Krams SM , Martinez OM . Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas . Cancer Res . 2003;63:4472–4480
  51. Kahan B , Knight R , Schoenberg L , et al.   Ten years of sirolimus therapy for human renal transplantation (the University of Texas at Houston experience) . Transplant Proc . 2003;35:25S–27S
  52. Haque T , Thomas JA , Falk KI , Parratt R , Hunt BJ , Yacoub M , et al.   Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients . J Gen Virol . 1996;77:1169–1172
  53. Alfieri CTJ, Carpentier L, Perpete C, Savoie A, Paradis K, Delage G, et al. Epstein-Barr virus transmission from a blood donor to an organ transplant recipient with recovery of the same virus strain from the recipient’s blood and oropharynx . Blood . 1996;87:812–817
  54. Hopwood PA , Brooks L , Parratt R , Hunt BJ , Bokhari M , Thomas JA , et al.   Persistent Epstein-Barr virus infection (unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients) . Transplantation . 2004;74:194–202
  55. Opelz G , Henderson R . Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients . Lancet . 1993;342:1514–1516
  56. Cockfield SM . Identifying the patient at risk for post-transplant lymphoproliferative disorder . Transplant Infect Dis . 2001;3:70–78
  57. Opelz G , Dohler B . Lymphomas after solid organ transplantation (a collaborative transplant study report) . Am J Transplant . 2004;4:222–230
  58. Petit B , Le Meur Y , Jaccard A , Paraf F , Robert CL , Bordessoule D , et al.   Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation . Transplantation . 2002;73:265–271
  59. Paya CVFJJ , Nalesnik MA , Kieff E , Green M , Gores G , Habermann TM , et al.   Epstein-Barr virus-induced posttransplant lymphoproliferative disorders . Transplantation . 1999;68:1517–1525
  60. Green MMMG , Webber SA , Rowe D , Reyes J . The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients . Pediatr Transpl . 1999;3:271–281
  61. Davis CL . The antiviral prophylaxis of post-transplant lymphoproliferative disease . Springer Semin Immunopathol . 1998;20:437–453
  62. McDiarmid SV , Jordan S , et al.   Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients . Transplantation . 1998;66:1604–1611
  63. Lee TCSB , Rooney CM , Heslop HE , Gee AP , Caldwell Y , Barshes NR , et al.   Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients . Am J Transpl . 2005;5:2222–2228
  64. Smets FLD , Bazin H , Reding R , Otte J-B , Buts J-P , Sokal EM . Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease . Transplantation . 2002;73:1603–1610
  65. Dotti GR , Fiocchi  , et al.   Lymphomas occurring late after solid-organ transplantation (influence of treatment on the clinical outcome) . Transplantation . 2002;74:1095–1102
  66. Ghobrial IMHTM , Ristow KM , Ansell SM , Macon W , Geyer SM , McGregor CG . Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era . Leuk Lymph . 2005;46:191–196
  67. Yang JVM , Lemas  , et al.   Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens . Blood . 2000;95:241–248
  68. Trofe JBJ, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG, et al. The Israel Penn International Transplant Tumor Registry 32 year experience with 402 renal transplant recipients with post transplant lymphoproliferative disease (multivariate analysis of risk factors that influence survival) . Am J Transplant . 2005;5:775–780
  69. Gross TGBJ , Park J , Greiner TC , Hinrich SH , Kaufman S , Langnas A , et al.   Low dose chemotherapy for the treatment of refractory post-transplant lymphoproliferative disease in children . J Clin Oncol . 2005;23:6481–6488
  70. Ghobrial IM , Habermann TM , Macon WR , et al.   Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients (are they two different diseases?) . Transplantation . 2005;79:244–247
  71. Leblond VN , Dhedin  , et al.   Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders . J Clin Oncol . 2002;19:772–778
  72. Buell JFGT, Hanaway MJ, Trofe J, Muthiak C, First RM, Alloway RR, et al. Chemotherapy for PTLD (The Israel Penn International Transplant Tumor Registry Experience) . Transplant Proc . 2005;37:956–957
  73. Hayashi RJ , Kraus MD , et al.   Posttransplant lymphoproliferative disease in children (correlation of histology to clinical behavior) . J Pediatr Hematol Oncol . 2001;23:14–18
  74. Aull MJ , Buell JF , et al.   MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature . Transplantation . 2003;75:225–228
  75. Swinnen LJ , LeBlanc M , et al.   Phase II study of sequential reduction in immunosuppression, interferon alpha-2b, and ProMACE-CytaBOM chemotherapy for post-transplant lymphoproliferative disorder (PTLD) (SWOG/ECOGS9239) . Blood . 2003;102:403a
  76. Swinnen LJ , Mullen GM , et al.   Aggressive treatment for postcardiac transplant lymphoproliferation . Blood . 1995;86:3333–3340
  77. Penn I . De novo malignancies in Pediatric Organ Transplant Recipients . Pediatr Transplant . 1998;2:56–63

PII: S1055-8586(06)00029-1

doi: 10.1053/j.sempedsurg.2006.03.005

Seminars in Pediatric Surgery
Volume 15, Issue 3 , Pages 179-187 , August 2006

Article Tools

* Image Usage & Resolution